ArticleJournal of the National Cancer Institute2023
Recommendations for Epstein-Barr virus-based screening for nasopharyngeal cancer in high- and intermediate-risk regions.
Open access · hybridAbstract read
In one paragraph
Article in Journal of the National Cancer Institute, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
9.2field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Systematic Review of AI-Driven Applications for Screening Nasopharyngeal Carcinoma Using MRI.Journal of magnetic resonance imaging : JMRI · 2026Pooled it
- Biomarkers of response to camrelizumab combined with apatinib: an analysis from a phase II trial in recurrent/metastatic nasopharyngeal carcinoma.British journal of cancer · 2025Trial
- Global burden of cancer attributable to infections in 2024: a worldwide incidence analysis.The Lancet. Oncology · 2026Article
- Nasopharyngeal carcinoma: epidemiology, risk factors, signaling pathways, clinical features, diagnosis, and management.Molecular biomedicine · 2026Review
- Epstein-Barr virus based biomarkers and targeted therapies in nasopharyngeal carcinoma: a narrative review.The Lancet regional health. Western Pacific · 2026Review
- A high-throughput Epstein-Barr virus nuclear antigen 1 (EBNA1) serology test strip for nasopharyngeal carcinoma risk screening.medRxiv : the preprint server for health sciences · 2026Article
- The burden of nasopharyngeal carcinoma in countries of the Association of Southeast Asian Nations (ASEAN), 1990-2023: findings from the Global Burden of Disease Study 2023.Journal of cancer research and clinical oncology · 2026Article
- Review
- Achieving control of nasopharyngeal carcinoma: the role of Epstein-Barr virus-based screening and vaccines.Nature reviews. Clinical oncology · 2026Review
- Population-based nasopharyngeal carcinoma survival in southern China.British journal of cancer · 2026Article
- Epstein-Barr Virus Detection in Lymphoproliferative Disorders: Epidemiological Characterization in Western Mexico.Infectious disease reports · 2025Article
- Diagnostic performance of EBV DNA load testing for nasopharyngeal carcinoma in nasopharyngeal swab outperforms the approach in other specimens.BMC cancer · 2025Article
- MB based RT-qPCR increase the clinical application of cfEBV DNA for NPC in non-endemic area of China.Scientific reports · 2025Article
- Change in diffusion weighted imaging after induction chemotherapy outperforms RECIST guideline for long-term outcome prediction in advanced nasopharyngeal carcinoma.Cancer imaging : the official publication of the International Cancer Imaging Society · 2025Article
- High IgG titers against EBV glycoprotein 42 correlate with lower risk of nasopharyngeal carcinoma.The Journal of clinical investigation · 2025Article
- Identification of B cell antigens in solid cancer: initial insights and functional implications.Frontiers in immunology · 2025Review
- The Epstein-Barr Virus Nuclear Antigen 1 Variant Associated with Nasopharyngeal Carcinoma Defines the Sequence Criteria for Serologic Risk Prediction.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
- Kinetics of EBV antibody-based NPC risk scores in Taiwan NPC multiplex families.International journal of cancer · 2024Article
- CRISPR for companion diagnostics in low-resource settings.Lab on a chip · 2024Review
- VLDL and LDL Subfractions Enhance the Risk Stratification of Individuals Who Underwent Epstein-Barr Virus-Based Screening for Nasopharyngeal Carcinoma: A Multicenter Cohort Study.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
35 authors at 17 institutions in 8 countries.
W K Jacky LamLi Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong SAR, China.ORCID 0000-0001-8922-5609
Ann D KingDepartment of Imaging and Interventional Radiology, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR, China.ORCID 0000-0002-5280-8349
Jacob A MillerDepartment of Radiation Oncology, Stanford University, Stanford, CA, USA.ORCID 0000-0002-8480-5492
Zhiwei LiuDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA.ORCID 0000-0002-0136-651X
Kelly J YuDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA.
Melvin L K ChuaDepartment of Head and Neck and Thoracic Cancers, Division of Radiation Oncology, National Cancer Centre Singapore, Singapore, Singapore.
Brigette B Y MaState Key Laboratory of Translational Oncology, Sir YK Pao Centre for Cancer, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR, China.
Ming Yuan ChenDepartment of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.
Benjamin A PinskyDepartment of Pathology, Stanford University, Stanford, CA, USA.ORCID 0000-0001-8751-4810
Pei-Jen LouDepartment of Otolaryngology, National Taiwan University Hospital and College of Medicine, Taipei, Taiwan.
John K S WooDepartment of Otorhinolaryngology, Head and Neck Surgery, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR, China.
Wan-Lun HsuMaster Program of Big Data in Biomedicine, College of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan.
Julia SimonInfections and Cancer Epidemiology, Infection, Inflammation and Cancer Program, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Denise L DoolanAustralian Institute of Tropical Health and Medicine, James Cook University, Cairns, Australia.
Tim WaterboerInfections and Cancer Epidemiology, Infection, Inflammation and Cancer Program, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Edwin P HuiState Key Laboratory of Translational Oncology, Sir YK Pao Centre for Cancer, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR, China.
Hui LiDepartment of Radiology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangzhou, China.
Raymond K TsangDepartment of Otolaryngology-Head and Neck Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Kenneth C W WongState Key Laboratory of Translational Oncology, Sir YK Pao Centre for Cancer, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR, China.
Julian P GohDepartment of Diagnostic Radiology, Tan Tock Seng Hospital, Singapore, Singapore.
Alexander C VlantisDepartment of Otorhinolaryngology, Head and Neck Surgery, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR, China.
Qi Yong AiDepartment of Imaging and Interventional Radiology, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR, China.
Lun M WongDepartment of Imaging and Interventional Radiology, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR, China.
Victor AbdullahDepartment of Otorhinolaryngology, Hong Kong Children's Hospital, Hong Kong SAR, China.
Jin Ching LinDepartment of Radiation Oncology, Changhua Christian Hospital, Changhua, Taiwan.
Chien-Jen ChenGenomics Research Center, Academia Sinica, Taipei, Taiwan.
Ruth M PfeifferDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA.
Quynh-Thu LeDepartment of Radiation Oncology, Stanford University, Stanford, CA, USA.ORCID 0000-0002-3682-1439
Anne W M LeeClinical Oncology Center, Shenzhen Key Laboratory for Cancer Metastasis and Personalized Therapy, The University of Hong Kong-Shenzhen Hospital, Guangdong, China.
Mingfang JiCancer Research Institute of Zhongshan City, Zhongshan City People's Hospital, Zhongshan, China.ORCID 0000-0003-4727-2858
Sumei CaoState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Center for Precision Medicine of Sun Yat-sen University, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.
Jun MaState Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Center for Precision Medicine of Sun Yat-sen University, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.ORCID 0000-0002-1137-9349
Anthony T C ChanState Key Laboratory of Translational Oncology, Sir YK Pao Centre for Cancer, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR, China.
K C Allen ChanLi Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong SAR, China.ORCID 0000-0003-1780-1691
Allan HildesheimAgencia Costarricense de Investigaciones Biológicas (ACIB) - Fundacion del Instituto Costarricense de Investigación y Enseñanza en Nutrición y Salud (INCIENSA), San José, Costa Rica.
Chinese University of Hong Kong · HKSun Yat-sen University · CNNational Cancer Institute · USStanford University · USGerman Cancer Research Center · DEAustralian Institute of Tropical Health and Medicine · AUChanghua Christian Hospital · TWDuchess of Kent Children's Hospital · CNDuke-NUS Medical School · SGFu Jen Catholic University · TWGenomics Research Center, Academia Sinica · TWHong Kong Polytechnic University · HKInstituto Costarricense de Investigación y Enseñanza en Nutrición y Salud · CRNational Taiwan University Hospital · TWNational University of Singapore · SGTan Tock Seng Hospital · SGZhongshan People's Hospital · CN
Funding
Viral and Host Factors Associated with NPCZIACP010211 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI ENGELS, ERIC A · 2010 to 2025
$6.1MAbstract
A meeting of experts was held in November 2021 to review and discuss available data on performance of Epstein-Barr virus (EBV)-based approaches to screen for early stage nasopharyngeal carcinoma (NPC) and methods for the investigation and management of screen-positive individuals. Serum EBV antibody and plasma EBV DNA testing methods were considered. Both approaches were found to have favorable performance characteristics and to be cost-effective in high-risk populations. In addition to endoscopy, use of magnetic resonance imaging (MRI) to investigate screen-positive individuals was found to increase the sensitivity of NPC detection with minimal impact on cost-effectiveness of the screening program.
Indexed as
CarcinomaEpstein-Barr Virus InfectionsNasopharyngeal NeoplasmsDNA, ViralEarly Detection of CancerHerpesvirus 4, HumanHumansNasopharyngeal CarcinomaDNA, Viral
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.